Product Description
Larotrectinib is used to treat a certain type of solid tumors in adults and children 1 month of age and older that have spread to other parts of the body or cannot be treated successfully with surgery. This medication is used only if there are no other treatments available and the tumors have worsened after receiving other treatments. Larotrectinib is in a class of medications called kinase inhibitors. It works by blocking the action of the abnormal protein that tells the cancer cells to multiply. This may help slow the growth of tumors. (Sourced from: https://medlineplus.gov/druginfo/meds/a619006.html)
Mechanisms of Action: TRKA Inhibitor,TRKB Inhibitor,TRKC Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Australia | Austria | Bangladesh | Belgium | Brazil | Canada | Colombia | Croatia | Cyprus | Czech | Denmark | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | Ireland | Israel | Italy | Japan | Korea | Latvia | Lithuania | Luxembourg | Netherlands | Norway | Poland | Portugal | Russia | Saudi Arabia | Singapore | Slovakia | Slovenia | Spain | Sweden | Switzerland | Taiwan | Turkey | United Kingdom | United States
Approved Indications: None
Known Adverse Events: None
Company: Bayer
Company Location: LEVERKUSEN 2M D-51368
Company CEO: Werner Baumann
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: China, Czech Republic, Denmark, France, Germany, Ireland, Italy, Japan, Netherlands, Portugal, Singapore, South Korea, Spain, Sweden, United States, Unknown Location
Active Clinical Trial Count: 6
Highest Development Phases
Phase 2: Central Nervous System Cancer|Lymphoma, Non-Hodgkin|Multiple Myeloma|Oncology Solid Tumor Unspecified|Thyroid Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 20289 | P2 |
Active, not recruiting |
Oncology Solid Tumor Unspecified |
2025-10-31 |
12% |
| 20290 | P2 |
Active, not recruiting |
Central Nervous System Cancer |
2026-09-01 |
12% |
| CTR20190625 | P2 |
Active, not recruiting |
Oncology Solid Tumor Unspecified |
None |
|
| JapicCTI-194842 | P2 |
Active |
Central Nervous System Cancer |
2020-09-30 |
|
| TAPUR | P2 |
Recruiting |
Lymphoma, Non-Hodgkin|Multiple Myeloma |
2027-12-31 |
12% |
| NCT05783323 | P2 |
Recruiting |
Thyroid Cancer |
2026-10-01 |
12% |